Risk of HAART therapy in hepatitis C

Hepatology. 2002 Mar;35(3):730. doi: 10.1053/jhep.2002.32094.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Drug Interactions
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Recombinant Proteins
  • Ribavirin / adverse effects*
  • Risk

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Ribavirin